TR201707764A2 - Split tablet forms of deferasirox. - Google Patents

Split tablet forms of deferasirox. Download PDF

Info

Publication number
TR201707764A2
TR201707764A2 TR2017/07764A TR201707764A TR201707764A2 TR 201707764 A2 TR201707764 A2 TR 201707764A2 TR 2017/07764 A TR2017/07764 A TR 2017/07764A TR 201707764 A TR201707764 A TR 201707764A TR 201707764 A2 TR201707764 A2 TR 201707764A2
Authority
TR
Turkey
Prior art keywords
deferasirox
tablet forms
split tablet
split
forms
Prior art date
Application number
TR2017/07764A
Other languages
Turkish (tr)
Inventor
Kandemi̇rer Ürün
Çi̇fter Ümi̇t
Yazici Gülnur
Original Assignee
Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/07764A priority Critical patent/TR201707764A2/en
Priority to PCT/TR2018/050241 priority patent/WO2019004985A2/en
Publication of TR201707764A2 publication Critical patent/TR201707764A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Buluş, vücutta aşırı miktarda demir birikimi ile ortaya çıkan durumların tedavisinde kullanılmak üzere; deferasiroksun veya onun farmasötik olarak kabul edilebilir bir tuzunun bölünebilir tablet formları ile ilgilidir.The invention is intended for use in the treatment of conditions associated with excessive iron accumulation in the body; relates to divisible tablet forms of deferasirox or a pharmaceutically acceptable salt thereof.

TR2017/07764A 2017-05-29 2017-05-29 Split tablet forms of deferasirox. TR201707764A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2017/07764A TR201707764A2 (en) 2017-05-29 2017-05-29 Split tablet forms of deferasirox.
PCT/TR2018/050241 WO2019004985A2 (en) 2017-05-29 2018-05-17 Dividable tablet forms of deferasirox

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/07764A TR201707764A2 (en) 2017-05-29 2017-05-29 Split tablet forms of deferasirox.

Publications (1)

Publication Number Publication Date
TR201707764A2 true TR201707764A2 (en) 2018-12-21

Family

ID=64742490

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/07764A TR201707764A2 (en) 2017-05-29 2017-05-29 Split tablet forms of deferasirox.

Country Status (2)

Country Link
TR (1) TR201707764A2 (en)
WO (1) WO2019004985A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
WO2009092601A1 (en) * 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
TWI686215B (en) * 2013-03-08 2020-03-01 瑞士商諾華公司 Oral formulations of deferasirox

Also Published As

Publication number Publication date
WO2019004985A2 (en) 2019-01-03
WO2019004985A3 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JOP20200011A1 (en) Compounds and formulations for treating conditions associated with NLRP activity
MX2022002579A (en) Aminothiazole compounds as c-kit inhibitors.
MX2021005529A (en) Compounds and compositions for treating conditions associated with nlrp activity.
NZ736665A (en) Heterocyclic amides as kinase inhibitors
MX2019011825A (en) Treatment of inflammatory diseases with inhibitors of c5a activity.
MX2015014582A (en) Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w.
MX386598B (en) ANTIBACTERIAL COMPOUNDS.
TR201808169T3 (en) Recombinant probiotic bacteria.
TW201613872A (en) IRAK4 inhibiting agents
BR112015019627A2 (en) heterocyclic amides as kinase inhibitors
MX385283B (en) CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT INHIBITOR.
MX2017015226A (en) TETRASUSTITUID ALQUENO COMPOUNDS AND ITS USE.
PH12017500095A1 (en) Imidazopyridazine compounds
BR112017000730B8 (en) PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS, AND DRUGS
EP4501406A3 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
MX2020008195A (en) Compounds for the treatment of pain.
EA033342B1 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
MX382092B (en) Heterocyclic compounds for the treatment of disease
EA201890212A1 (en) NEW DEXTRAN SULFATE APPLICATION
MX2018002018A (en) Urea derivative and use therefor.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
TR201707764A2 (en) Split tablet forms of deferasirox.
MX2020003575A (en) New alcoxyamino derivatives for treating pain and pain related conditions.
MX375860B (en) USE OF 2-(5S-METHYL-2-OXO-4R-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE IN THE TREATMENT OF SEIZURES.
TR201718945A2 (en) A production method for the pharmaceutical product containing deferasirox.